Webinar
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
Date: September 18, 2025 | 2:00 PM
When: Thursday, September 18 | 2 p.m. EST
The 5-year CHECKMATE-9ER follow-up offers the most extensive data to date on CABOMETYX + OPDIVO in first-line advanced renal cell carcinoma — including long-term survival outcomes, safety signals, and quality-of-life measures across diverse patient groups.
In this session, Jennifer Hasiak, PharmD from Hematology & Oncology Consultants will:
- Review efficacy and safety data from the primary analysis and extended follow-up
- Examine exploratory findings on quality of life and sites of metastasis
- Outline dosing strategies and management of treatment-related adverse events
- Translate trial evidence into practical guidance for clinical practice
Gain the insight you need to make evidence-based decisions and optimize care for patients with aRCC.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
June 25, 2026 | 2:00 PM
Upcoming Webinar
Techs Talk The Importance of Oral Health for Oncology Patients
July 8, 2026 | 3:00 PM